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loom syndrome (BS) is a hereditary disorder charac-
terized by pre- and postnatal growth retardation,
genomic instability, and cancer. 
 
BLM
 
, the gene de-
fective in BS, encodes a DNA helicase thought to participate
 
in genomic maintenance. We show that BS human ﬁbroblasts
undergo extensive apoptosis after DNA damage speciﬁ-
cally when DNA replication forks are stalled. Damage
during S, but not G
 
1
 
, caused BLM to rapidly form foci with
 
 
 
H2AX at replication forks that develop DNA breaks.
 
These BLM foci recruited BRCA1 and NBS1. Damaged
B
 
BS cells formed BRCA1/NBS1 foci with markedly delayed
kinetics. Helicase-defective BLM showed dominant-negative
 
activity with respect to apoptosis, but not BRCA1/NBS1
recruitment, suggesting catalytic and structural roles for
BLM. Strikingly, inactivation of p53 prevented the death of
damaged BS cells and delayed recruitment of BRCA1/
NBS1. These ﬁndings suggest that BLM is an early responder
to damaged replication forks. Moreover, p53 eliminates cells
 
that rapidly assemble BRCA1/NBS1 without BLM, suggesting
that BLM is essential for timely BRCA1/NBS1 function.
 
Introduction
 
Bloom syndrome (BS) is a rare genetic disorder caused by
inactivating mutations in BLM, a member of the RECQ
helicase family (Hickson et al., 2001). There are five human
RECQ-like proteins (RECQL1, BLM, WRN, RECQL4,
and RECQ5), each having 3
 
 
 
 to 5
 
 
 
 DNA helicase activity
but little sequence similarity outside the helicase motifs.
Three of these helicases (BLM, WRN, and RECQL4) cause
a clinical syndrome when deficient (van Brabant et al.,
2000). These syndromes (Bloom, Werner, and Rothmund-
Thomson, respectively) all show genomic instability and
cancer susceptibility, but each also has distinctive features.
The unique features of BS are severe pre- and postnatal
growth retardation and a wide spectrum of cancers that
develop at a young age. Other BS phenotypes include facial
sun sensitivity, immunodeficiency, and male sterility/female
subfertility (German, 1969, 1997). Werner syndrome, by
contrast, is an adult progeria characterized by multiple signs
of aging that develop two to three decades prematurely.
These aging phenotypes include cataracts, thin gray hair,
atherosclerosis, osteoporosis, and type II diabetes. Werner
 
syndrome individuals also develop cancer, but 
 
 
 
50%
mesenchymal tumors, which are rare in the general aged
population (Martin, 1997). Rothmund-Thomson syndrome
presents with skin and skeletal abnormalities and a high
incidence of skin and bone neoplasms (Vennos and James,
1995). Thus, BS is the only RECQ-related disorder that
results in the range and types of cancer observed in the
general aged population (German, 1993). BS patients die
predominantly of cancer in the second or third decade of
 
life, much earlier than individuals with Werner or Rothmund-
Thomson. Thus, BLM must participate in a process that is
vital from early development and that, when defective,
predisposes individuals to very early onset of cancer.
Many genes that are mutated in human disorders are
structurally or functionally conserved in lower eukaryotes,
including yeast (Frei and Gasser, 2000b). Nonetheless,
human disease genes rarely correct phenotypes resulting
from mutations in the corresponding yeast gene. A notable
exception is BLM and WRN, which complement defects in
SGS1, the single RECQ homologue in the budding yeast
 
Saccharomyces cerevisiae
 
. BLM or WRN suppresses the hyper-
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recombination phenotype of 
 
sgs1
 
 mutant yeast, although
only BLM restores the slow growth and hydroxyurea (HU)
resistance of 
 
top1:sgs1
 
 double mutants (Yamagata et al.,
1998). The HU sensitivity of 
 
sgs1
 
 mutants is noteworthy
because HU inhibits ribonucleotide reductase, thereby hin-
dering DNA replication fork progression (Koc et al., 2003).
Like BS cells, 
 
sgs1
 
 mutants are genomically unstable, accu-
mulating chromosome translocations, chromosome dele-
tions, and sister chromatid exchanges, the most common
chromosomal abnormality in BS (Onoda et al., 2000). Fis-
sion yeast (
 
Schizosaccharomyces pombe
 
) show similar pheno-
types upon inactivation of its single RECQ homologue,
RQH1/RAD12. 
 
Rqh1/rad12
 
 mutants are hypersensitive to
HU (Stewart et al., 1997), showing chromosomal abnor-
malities and hyper-recombination after exposure. Thus,
yeast BLM orthologues may be cell cycle–dependent sen-
sors and/or early responders to DNA damage. Indeed, re-
cent findings suggest that Sgs1p signals to the S phase
checkpoint machinery, intriguingly through protein–pro-
tein interactions outside the helicase domain (Frei and
Gasser, 2000b).
Indirect evidence suggests that BLM may likewise play a
role in sensing and repairing DNA damage in mammalian
cells (van Brabant et al., 2000); for example, the recent ob-
servation that Epstein Barr virus–transformed BS lympho-
blasts fail to form NBS1/MRE11 foci after exposure to HU
(Franchitto and Pichierri, 2002). Here, we examine the role
of BLM in the DNA damage response using human fibro-
blasts with intact damage checkpoints. We show that BS
cells, or normal cells that express a helicase-defective BLM,
die by apoptosis in response to diverse genotoxins. This sen-
sitivity was limited to S phase, during which time damage
rapidly mobilized BLM from its location in promyelocytic
leukemia protein (PML) bodies to DNA breaks. We show
that BLM is required for rapid recruitment of BRCA1 and
NBS1 to the damage, but interestingly, this recruitment did
not require BLM helicase activity. Of particular importance,
BS cells deficient in p53 function did not die when damaged
Figure 1. Human cells expressing wild-type or mutant BLM proteins. (a) Protein expression. NHFs and BSFs were immortalized by hTERT 
and then infected with retroviruses carrying no insert (NHF and BSF) or cDNAs encoding wild-type ( BLM) or mutant ( HM) BLM proteins 
as described in the Materials and methods. Proteins from asynchronous cultures were analyzed for BLM and tubulin (control) by Western 
blotting and quantified by densitometry. Relative BLM levels (Expression) were determined by dividing the BLM signal by the tubulin signal, 
setting the NHF value at 1.0. (b) BLM localization. Cells described in part a were stained for BLM (green) and PML (red), and the images were 
merged using Adobe Photoshop
®. Nuclei were counterstained with DAPI (blue). Bars, 10  m.T
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in S phase, nor did they delay BRCA1/NBS1 recruitment
into foci. We suggest that our findings help explain the
growth retardation and cancer predisposition of BS.
 
Results
 
hTERT immortalized BS and complemented fibroblasts
 
To study BLM function in untransformed cells, we devel-
oped isogenic human fibroblasts that lack or express BLM.
First, we used a retrovirus to express the catalytic subunit of
telomerase (hTERT) into normal (normal human fibroblast
[NHF]) and BS (Bloom syndrome fibroblast [BSF]) strains.
hTERT immortalizes cells (Bodnar et al., 1998; Vaziri et al.,
1999) without disrupting cell cycle checkpoints (Jiang et al.,
1999; Toouli et al., 2002). hTERT rescued three NHFs
(82-6, HCA2, and WI-38) and two BSFs (HG2654 and
 
HG1013) from replicative senescence (Kim et al., 1999; un-
published data), as expected.
We next used retroviruses to introduce a control (insert-
less) vector or one that expresses either wild-type BLM or a
mutant protein (helicase mutant [HM]) harboring a single
amino acid substitution (K695T) that abolishes helicase ac-
tivity (Neff et al., 1999). Wild-type or HM BLM is toxic
when overexpressed in untransformed cells (Yankiwski et
al., 2000; unpublished data). We therefore selected an un-
cloned population of low expressers from mass infected cul-
tures (see Materials and methods). Western analysis con-
firmed that BLM is undetectable in control BS cells and
that the retrovirus expressed wild-type and mutant BLM at
levels similar to that of endogenous BLM in normal cells
(Fig. 1 a). Immunostaining showed that 
 
 
 
90% of BS cells
expressed the retroviral proteins, and that they localized pri-
Figure 2. BS cells are sensitive to DNA damaging agents. (a) Etoposide sensitivity. Asynchronous NHF1 and 2 (82-6 and HCA2) and BSF1 
and 2 (HG1013 and HG2654) cells were treated with the indicated doses of etoposide for 1 h and scored 6 h later for loss of mitochondrial 
membrane potential (% Apoptotic Cells), as described in the Materials and methods. (b and c) BS cells die by apoptosis. NHFs (82-6), BSFs 
(HG2654), and complemented BSFs (BSF   BLM) were synchronized in S phase as described in the text and the Materials and methods and 
then left untreated ( ) or treated ( ) for 1 h with etoposide (20  g/ml) or HU (30 mM; not depicted). 6 h later, cells were fixed and stained 
with DAPI to observe nuclear morphology (b). Nuclear blebbing or fragmentation (arrows and inset) was observed in  50% treated BSFs and 
in  5% treated NHF and BSF   BLM cells. Alternatively, untreated or etoposide-treated (Etop) cells were analyzed for activated caspase-3 
(Casp-3 Activity) in the absence or presence of DEVD, a caspase-3 inhibitor (c), as described in the Materials and methods. (d) Effect of 
wild-type and mutant BLM. Asynchronous BSF (HG2654), complemented BSF (BSF   BLM), NHFs (82-6), and mutant BLM expressing NHF 
(NHF   HM) were treated with the indicated doses of etoposide for 1 h and scored for apoptosis as described in part a. (e) Sensitivity to other 
agents. Asynchronous NHF, BSF, and BSF   BLM cells were untreated (Unt), X irradiated (5 Gy; IR), or treated for 2 h with 20  g/ml bleomycin 
(Bleo) or 2  g/ml mitomycin C (MMC), and scored for apoptosis as described in part a. Error bars show the standard error from at least two 
independent experiments.T
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marily to PML nuclear bodies (Fig. 1 b), the sites to which
endogenous BLM localizes when it is expressed in S and G
 
2
 
(Bischof et al., 2001b).
 
Asynchronous BS cells are mildly sensitive 
to genotoxic agents
 
To assess sensitivity to DNA damage, we treated asynchro-
nous cultures for 1 h with etoposide, a topoisomerase II in-
hibitor that causes double strand DNA breaks (Sinha,
1995). 6 h later, we scored the cells for signs of apoptosis:
loss of mitochondrial membrane potential (Fig. 2 a), nu-
clear blebbing (Fig. 2 b), and activated caspase-3 (Fig. 2 c)
(Green and Reed, 1998). At all concentrations tested, the
two BSFs were one- to twofold more sensitive than two
NHFs (Fig. 2 a). More importantly, wild-type BLM res-
cued this sensitivity (Fig. 2, b–d). Conversely, the HM mu-
tant rendered NHFs as sensitive as BSF (Fig. 2 d), suggest-
ing that it has dominant-negative activity. Comparable
results were obtained when we similarly treated with X-rays,
bleomycin (a radiomimetic), or mitomycin C (an alkylating
agent); in all cases, BSFs were one- to twofold more sensi-
tive than NHFs (Fig. 2 e).
 
BSFs are sensitive in S phase, but not G1
 
Because BLM expression peaks in S phase and G
 
2
 
 (Bischof
et al., 2001b), and mutant RECQ proteins render yeast
hypersensitive to replication inhibitors such as HU (Yama-
gata et al., 1998), we asked whether BSFs were selectively
sensitive to DNA damage during S phase. We cultured
NHF, NHF 
 
  
 
HM, BSF, and BSF 
 
  
 
BLM cells in se-
rum-deficient medium for 72 h. All cell types became qui-
escent (
 
 
 
95% G
 
1
 
 DNA content; 
 
 
 
2% cells in S phase),
similar to unmodified cells (unpublished data). Thus, the
hTERT immortalization and other infections did not per-
turb normal growth control. We then stimulated quiescent
cells to enter G
 
1
 
 by providing serum for 4–6 h and chal-
lenged with etoposide or bleomycin for 1 h. 6 h later, we
assessed the cells for apoptosis. All four cell types showed
low sensitivity to etoposide (Fig. 3 a) and bleomycin (not
depicted). Thus, BS cells were not hypersensitive to DNA
damage in G
 
1
 
.
 
To examine sensitivity in S phase, we serum stimulated
quiescent NHF, BSF, and BSF 
 
  
 
BLM cells for 8 h and
then added aphidicolin for 12–14 h to arrest them at the G
 
1
 
/S
boundary. We then cultured in drug-free medium to allow
progression into S phase. After 1 h (early S phase), we added
etoposide for 1 h and scored for apoptosis 6 h later. In con-
trast to their relative insensitivity in G
 
1
 
, BSFs were hypersen-
sitive to etoposide in early S (Fig. 3 b). Moreover, BLM
complementation attenuated this sensitivity (Fig. 3 b). Cell
death was somewhat greater when BSFs were damaged dur-
ing S phase rather than asynchronous growth (Fig. 2, a and
d, versus Fig. 3 b), and greater yet when the synchrony was
improved (see next section). Thus, BSFs were hypersensitive
to DNA damage selectively during S phase.
Of significance, both asynchronous (not depicted) and S
phase (Fig. 3 c) BSFs underwent apoptosis when treated
with HU, which stalls replication forks (Koc et al., 2003). At
10–30 mM, a 1-h exposure to HU caused as much cell
death in 6 h as a 1-h exposure to etoposide (Fig. 3, a and b).
A lower dose (1 mM), which still retards replication forks,
also caused apoptosis, albeit after a longer interval (Fig. S1,
available at http://www.jcb.org/cgi/content/full/jcb.200304016/
DC1), consistent with the report that BS lymphoblasts die
36 h after exposure to 2 mM HU (Franchitto and Pichierri,
2002). This result suggests that BSFs are hypersensitive to
replication stress.
 
Slow growth of BLM-deficient cells
 
hTERT-immortalized BSFs proliferated slowly relative to
hTERT-expressing NHFs (doubling time 80–100 h versus
 
 
 
40 h; Fig. 4 a), as did unmodified BSFs (not depicted).
BLM complementation accelerated the growth of BSFs,
whereas the HM mutant retarded the growth of NHFs (Fig.
4 a). These growth rate differences affected the kinetics of S
phase entry after synchronization. We followed S phase en-
try after release from a G
 
1
 
/S block using 1-h pulses with
BrdU. Greater than 80% of NHF and BSF 
 
  
 
BLM cells in-
corporated BrdU 1 h after release, but 
 
 
 
50% of BSF and
NHF 
 
  
 
HM cells did so. However, 3 h after release, 
 
 
 
80%
of BSF and NHF 
 
  
 
HM cells incorporated BrdU (Fig. 4, b
and c). These findings indicate that the slow growth of BSF
Figure 3. BS cells are sensitive to damage in S phase but not G1. (a) Lack of sensitivity during G1. NHFs (82-6), mutant BLM-expressing 
NHFs (NHF   HM), BSFs (HG2654), and complemented BSF (BSF   BLM) were synchronized in G1 as described in the text and Materials 
and methods, treated with etoposide (20  g/ml) for 1 h, and scored for apoptosis 6 h later as described for Fig. 2 a. (b and c) Hypersensitivity 
during S phase. NHF, BSF, and BSF   BLM cells were synchronized in S phase as described in the text and the Materials and methods, treated 
with indicated doses of etoposide (b) or HU (c) for 1 h, and scored for apoptosis 6 h later. Shown is a representative experiment, which was 
repeated at least twice.T
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and NHF 
 
  
 
HM cells is not due to a smaller growth frac-
tion. Moreover, their slower entry into and exit from S
phase (Fig. 4 b) suggest that the slow growth is not due
solely to an increase in G
 
1
 
, consistent with the cell cycle dis-
tributions of asynchronous cells determined by flow cytome-
try (unpublished data). We therefore adjusted the synchro-
nization protocol in subsequent experiments (see Materials
and methods) and assessed sensitivity to etoposide and HU
when 
 
 
 
80% of cells were in early S (Fig. 4 c). Under these
conditions, BSF and NHF 
 
  
 
HM cells showed 
 
 
 
10-fold
more apoptosis than NHF or BSF 
 
  
 
BLM cells (Fig. 4, d
and e). Unmodified BSF cells also underwent extensive
apoptosis when given HU during S phase (Fig. S2 a, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200304016/
DC1), indicating that the cell death we observed was not
due to hTERT expression. We conclude that BLM is crucial
for cell survival during replication stress.
 
Death of BSFs is p53 dependent
 
Because the p53 tumor suppressor is a critical regulator of
apoptosis, we asked whether the death of BSFs is p53 de-
pendent. First, we reduced p53 in NHFs and BSFs by ex-
pressing E6, a viral protein that stimulates p53 degradation
(Dalal et al., 1996). We then synchronized the cells in early
S phase and stalled replication forks with HU. E6 did not
alter the modest apoptotic response of NHFs; however, it
completely abolished the robust apoptotic response of BSFs
(Fig. 5 a). Second, we expressed a dominant-negative p53
protein (V143A) (Matas et al., 2001) in BSFs. p53-V143
also abolished the apoptotic response to HU (Fig. 5a).
Western analysis confirmed that p53 levels were similar in
NHFs and BSFs, and that p53 was reduced by E6 in NHFs
Figure 4. Slow growth and S phase kinetics of BLM-deficient cells. (a) Proliferation rate. We plated NHF, NHF   HM, BSF, and BSF   BLM 
cells at subconfluent densities, counted cells every 2–4 d, and calculated population doubling times while the cells proliferated exponentially. 
(b) S phase kinetics. We synchronized cells at the G1/S boundary, released for the indicated times, added BrdU for 1 h, and then fixed and 
stained for BrdU as described in the text and the Materials and methods. (c) Optimized synchronization. We adjusted the synchronization of 
BSF, NHF   HM, NHF, and BSF   BLM cells as described in the Materials and methods and verified that  90% initiated S phase 1 h after 
release from a G1/S block by pulsing with BrdU for 1 h and scoring the % BrdU-labeled nuclei. (d and e) Sensitivity during S phase. NHF, 
NHF   HM, BSF, and BSF   BLM cells were synchronized at the G1/S boundary, released for 1 h, and given 20  g/ml etoposide (d) or 30 mM 
HU (e) for 1 h. We scored apoptosis 6 h later as described for Fig. 2 a.
Figure 5. BS cells undergo p53-dependent apoptosis. (a) Apoptosis. 
NHFs (WI-38) and BSFs (HG2654) were infected with retroviruses 
expressing either E6 or p53-V143A. The cells were then synchronized 
and treated in early S phase for 1 h with HU (30 mM). Apoptosis 
was scored 6 h later as described for Fig. 2 a. Error bars, standard 
error from two experiments. (b) p53 levels. Lysates from proliferating 
NHFs and BSFs infected with control, E6-expressing, or p53-V143A–
expressing retroviruses were analyzed for p53 or actin (control) by 
Western blotting.T
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(unpublished data) and elevated by expression of p53-
V143A in BSFs (Fig. 5 b). These results indicate that BLM
deficiency during replication stress engages the apoptotic
function of p53.
 
BLM rapidly localizes to double strand breaks 
during S phase
 
Stalled replication forks can develop double strand breaks
(Ward and Chen, 2001; Xu and Stern, 2003), which
are rapidly marked by phosphorylated histone H2AX
(
 
 
 
H2AX), foci of which are a very early marker of broken
DNA (Paull et al., 2000; Celeste et al., 2002). We therefore
asked whether BLM localized to DNA breaks marked with
 
 
 
H2AX when replication forks stall.
As expected (Paull et al., 2000; Bischof et al., 2001b; Fu-
ruta et al., 2003), undamaged NHFs in early S showed dif-
fuse 
 
 
 
H2AX and punctate BLM immunostaining (Fig. 6
a). When these cells were given bleomycin, which causes
random double strand breaks (Kaufmann and Kies, 1998),
multiple 
 
 
 
H2AX foci formed in most cells within 1 h (Fig.
 
6, a–c). Many (
 
 
 
70%) of these foci costained for BLM
(Fig. 6, a and b). When the cells were given HU, multiple
 
 
 
H2AX foci also formed, indicating that some stalled forks
acquired double strand breaks (Ward and Chen, 2001; Xu
and Stern, 2003). BLM localized to nearly 90% of these
foci (Fig. 6, a and b). BLM localized to 
 
 
 
H2AX foci rap-
idly, lagging behind 
 
 
 
H2AX focus formation by only a few
minutes (Fig. 6 c). Unmodified NHFs (lacking hTERT)
(Fig. S2 b) and complemented BS cells (Fig. S3, available at
http://www.jcb.org/cgi/content/full/jcb.200304016/DC1)
also showed rapid 
 
 
 
H2AX/BLM colocalization in response
to HU. Because bleomycin breaks DNA randomly, whereas
HU causes breaks at replication forks, these results suggest
that BLM localizes to replication forks that develop double
strand breaks. It is possible, however, that BLM localizes to
any double strand break during S phase. Whatever the case,
immunoprecipitation and Western analysis showed that
 
 
 
70% of 
 
 
 
H2AX coprecipitated with BLM when Jurkat
cells were given HU (Fig. 6 d), suggesting that BLM and
 
 
 
H2AX reside in a common complex after replication forks
Figure 6. BLM localizes with  H2AX. (a) BLM/ H2AX foci. NHF (82-6) cells were synchronized in early S phase and not treated (None) or 
treated with 20  g/ml bleomycin (Bleo) or 30 mM HU for 1 h. Cells were then immunostained for BLM (green) and  H2AX (red), and the 
images were merged. DAPI staining (blue) marks cell nuclei. Bars, 10  m. (b) Quantitation of BLM/ H2AX coincidence. Merged images from 
part a were analyzed for the percentage of  H2AX foci that costained for BLM, counting  100 nuclei per experiment. Error bars, standard 
error from two experiments. (c) Kinetics of  H2AX/BLM colocalization. NHFs in early S phase were given 30 mM HU and stained for  H2AX 
and BLM at the indicated intervals thereafter. Gray bars, % cells with  10  H2AX foci. Black bars, % cells in which  80% of  H2AX foci 
costained for BLM. (d) BLM– H2AX complex. Asynchronous Jurkat cells were untreated ( ) or treated ( ) with 10 mM HU for 6 h. Lysates 
were prepared, 90% was immunoprecipitated (IP) by control (IgG) or anti-BLM antibody, and immunoprecipitates were analyzed by Western 
blotting (WB) using anti- H2AX or anti-BLM antibodies. 10% of each lysate was analyzed directly by Western blotting (Input).T
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stall. Moreover,  70% of the BLM/ H2AX foci that
formed after HU treatment did not contain PML (unpub-
lished data), consistent with our finding that BLM dissoci-
ates from PML bodies in a fraction of asynchronous cells
treated with agents that break DNA (Bischof et al., 2001b).
Together, these findings suggest that BLM is recruited
from PML bodies to associate with double strand breaks
during S phase.
BSFs do not form NBS1 and BRCA1 foci immediately 
after replication stress
 H2AX foci are thought to recruit proteins such as NBS1
(Nijmegen breakage syndrome protein 1) and BRCA1
(breast cancer–associated protein 1) (Celeste et al., 2002;
Fernandez-Capetillo et al., 2003; Kobayashi et al., 2002),
which are important for optimal double strand break repair
(D’Amours and Jackson, 2002). BRCA1 colocalized with
BLM in a fraction of HU-treated carcinoma cells (Wang et
al., 2000), and BS lymphoblasts were reported deficient in
NBS1 foci (Franchitto and Pichierri, 2002). To determine
the relationship between BLM, BRCA1, and NBS1, we lo-
calized BLM in human carcinoma cells carrying a dominant-
negative BRCA1 allele (Scully et al., 1999) and hTERT-
immortalized, NBS1-deficient fibroblasts (see Materials
and methods). In undamaged cells, BLM localized primar-
ily to PML bodies (Fig. 7 a). Further, BLM localized to
many of the  H2AX foci that formed after exposure to HU
(Fig. S4, available at http://www.jcb.org/cgi/content/full/
jcb.200304016/DC1). These findings suggest that proper
BLM localization does not depend on BRCA1 or NBS1.
However, the rapid response of BRCA1 and NBS1 to repli-
cation stress depended on BLM.
In undamaged NHFs, BRCA1 was barely detectable in
G0/G1 (not depicted) but formed multiple (greater than five)
foci in early S (Fig. 7, b and d), consistent with BRCA1, like
BLM, being expressed during S phase (Scully and Living-
ston, 2000). A fraction (25–30%) of BRCA1 foci colocalized
with BLM and PML in undamaged cells, but the majority
( 80%) colocalized with BLM and  H2AX 1 h after repli-
cation was stalled by HU (not depicted). BSFs formed many
fewer BRCA1 foci. Cells with greater than five BRCA1 foci
comprised  20% of undamaged BSFs in S phase, and this
percentage did not increase 1 h after exposure to 30 mM
(Fig. 7, b and d) or 1 mM HU (Fig. S5 a, available at http://
www.jcb.org/cgi/content/full/jcb.200304016/DC1). West-
ern analysis showed that BLM did not alter BRCA1 protein
levels (not depicted), indicating that BLM affects BRCA1 lo-
calization, not expression. NBS1 focus formation was also
impaired in BSFs. Undamaged NHFs formed NBS1 foci
during S phase, as reported (Lombard and Guarente, 2000;
Miura et al., 2001). However, NBS1 foci were largely absent
from BSFs;  20% of undamaged cells contained greater
than five foci and this did not change 1 h after HU treat-
ment (Fig. 7, b and e; Fig. S5 a). Failure to form BRCA1
and NBS1 foci was due to BLM deficiency because these foci
formed normally in BLM-complemented BSFs (Fig. 7, b, d,
and e; Fig. S5 a). Further, this failure was not due to the syn-
chronization method, because BSFs synchronized by mi-
mosine and then treated for 1 h with HU in early S also
formed very few BRCA1 or NBS1 foci (Fig. S5, b and c).
BRCA1 was shown to reside in a complex with BLM in a
fraction of damaged, asynchronous HeLa cells (Wang et al.,
2000). Immunoprecipitation showed that NBS1 also resides
in a complex with BLM in asynchronous Jurkat cells treated
with bleomycin and NHFs treated with HU in S phase (Fig.
7, f and g). Taken together, these findings suggest that BLM
acts upstream of NBS1 and BRCA1 to assemble repair com-
plexes at damaged replication forks.
Despite failure to form BRCA1 or NBS1 foci in early S,
BSFs formed these foci later in S phase (6–8 h after release
from G1/S) (not depicted). Moreover, although many BSFs
did not form BRCA1/NBS1 foci 1 h after replication forks
stalled, they formed these foci 6 h later (Fig. 7, c–e). Thus,
BLM deficiency delayed, but did not abrogate, BRCA1 and
NBS1 recruitment into foci. Of interest, NHFs expressing
the HM mutant were completely normal in assembling
BRCA1/NBS1 foci during early S and 1 h after replication
forks stalled (Fig. 7 b). Thus, despite dominant-negative ac-
tivity with respect to growth and apoptosis, the HM mutant
did not have dominant-negative activity with respect to
BRCA1/NBS1 focus formation. This finding suggests that
BLM has a structural role, which does not depend on its he-
licase activity, in assembling BRCA1/NBS1 complexes.
p53-deficient BSFs rapidly assemble NBS1 and BRCA1 
foci after replication stress
In response to DNA damage, p53 halts cell cycle progres-
sion, presumably to allow repair, or induces apoptosis or se-
nescence if the damage is severe (Ryan et al., 2001). Recent
findings suggest that p53 may directly modulate repair or in-
teract with repair proteins (Lu et al., 2003; Maser and De-
Pinho, 2003; Rubbi and Milner, 2003). Because p53 medi-
ated the apoptotic response of BSFs to damaged replication
forks (Fig. 5), we asked whether p53 prevented the rapid as-
sembly of BRCA1/NBS1 foci in BSFs. In contrast to BSFs
with wild-type p53, 70–80% of BSFs with mutant p53
(p53-V143A) assembled BRCA1 and NBS1 foci 1 h after
HU stalled replication forks (Fig. 8, a and b). Loss of p53
function also partially restored the ability of undamaged
BSF to form NBS1, but not BRCA1, foci in S phase (Fig. 8
b). NHFs with mutant p53, in contrast, showed no change
in their relatively low incidence of apoptosis (Fig. 5 a), or
ability to form BRCA1/NBS1 foci (Fig. 8, c and d) 1 h after
HU stalled replication forks. These findings suggest that
p53 acts downstream of BLM, delaying BRCA1/NBS1 fo-
cus formation in the absence of BLM.
Discussion
BLM associates with double strand breaks during S phase
Studies in yeast and human cells suggest a pivotal role for
RECQ-like helicases in maintaining genomic integrity dur-
ing S phase (Bernstein et al., 2002; D’Amours and Jackson,
2002). Among the five human RECQ helicases, BLM ap-
pears to be particularly important in this regard (Ababou et
al., 2000; Dutertre et al., 2000; Sengupta et al., 2003). Al-
though in vitro data suggest that Xenopus RECQ proteins
play a direct role in DNA replication (Liao et al., 2000),
yeast and mammalian cell studies are more consistent with a
role for BLM in responding to DNA damage during replica-T
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Figure 7. Effects of BLM deficiency on 
BRCA1 and NBS1 foci. (a) BLM localiza-
tion in BRCA1- or NBS1-deficient cells. 
Asynchronous BRCA1 mutant cells 
(HCC1937, BRCA1
 /m) and NBS1-defi-
cient cells (GM07166A, NBS1
 / ) were 
immunostained for BLM and PML, and 
the images were merged. Bars, 10  m. 
(b) NHF (82-6), BSF (HG2654), comple-
mented BSF (BSF   BLM), and NHF 
expressing mutant BLM (NHF   HM) 
were synchronized in early S phase, left 
untreated ( ) or treated ( ) with 30 mm 
HU for 1 h, and immunostained for 
BRCA1 and NBS1. Nuclei were counter-
stained with DAPI (blue). Bars, 10  m. 
(c) Delayed BRCA1 and NBS1 focus 
formation in BSF. BSFs were synchro-
nized and treated with HU as described 
in part b. 6 h later, they were immuno-
stained for BRCA1 and NBS1. (d and e) 
Quantification of nuclei with BRCA1 or 
NBS1 foci. NHF (82-6), BSF (HG1013, 
BSF1; HG2654, BSF2), and comple-
mented HG2654 (BSF   BLM) cells 
were synchronized in early S phase, left 
untreated or treated with HU (30 mM) for 1 h, and then immunostained for BRCA1 (d) or NBS1 (e) foci. BSFs (HG2654) were also stained 6 h 
after treatment with HU (BSF/6h). Nuclei with greater than five BRCA1 or NBS1 foci were scored as positive. Error bars, standard error from 
two experiments. (f and g) NBS1–BLM complexes. Asynchronous Jurkat cells were untreated (Unt) or treated with 10  g/ml bleomycin (Bleo) T
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tion (Hickson, 2003), and particularly in repairing stalled
replication forks (Imamura et al., 2001; Ababou et al.,
2002; Sengupta et al., 2003). In contrast to many stud-
ies, we used isogenic, hTERT-immortalized, but untrans-
formed, BS fibroblasts in which we expressed normal or
helicase-deficient BLM proteins. These proteins were ex-
pressed at levels comparable to endogenous BLM in NHFs,
and localized to PML bodies. Although BLM can localize to
the nucleolus in some transformed cells, we and others find
BLM predominantly in PML bodies in normal cells (Yan-
kiwski et al., 2000; Bischof et al., 2001b). Our results show
unambiguously that BSFs, both unmodified and hTERT
immortalized, are hypersensitive to genotoxic stress only
during S phase. Virtually all the hypersensitivity was elimi-
nated by expressing wild-type BLM, and the HM mutant
conferred hypersensitivity to normal cells, indicating that
the hypersensitivity is a consequence of BLM deficiency.
We did not observe such striking cell cycle–dependent sen-
sitivity in hTERT-immortalized Werner syndrome fibro-
blasts (unpublished data).
In response to damage during S phase, BLM promptly left
the PML bodies and associated with DNA double strand
breaks, as assessed by loss of costaining with PML and gain
of costaining with  H2AX. The kinetics of costaining with
 H2AX, and ability of HU to cause BLM relocalization,
suggests that BLM rapidly localizes to double strand breaks
at replication forks. These results, and the finding that BSFs
fail to rapidly assemble BRCA1 or NBS1 foci after damage,
for 6 h (f), and NHFs (82-6) were synchronized in early S and untreated (Unt) or treated with 30 mM HU for 1 h. Lysates were prepared, 90% 
was immunoprecipitated (IP) by control (IgG) or anti-BLM antibody, and immunoprecipitates were analyzed by Western blotting (WB) using 
anti-BLM or anti-NBS1 antibodies. 10% of each lysate was analyzed directly by Western blotting (Input).
Figure 8. Localization of BRCA1 and NBS1 in BS cells with mutant p53. (a) Effect of mutant p53 in BSFs. BSFs (HG2654) expressing p53-
V143A were synchronized in early S phase and left untreated ( ) or treated ( ) with 30 mM HU for 1 h. They were then immunostained for 
NBS1 or BRCA1 as indicated, and the nuclei were counterstained with DAPI (blue). Bars, 10  m. (b) Quantitation. BSFs with wild-type (WT) 
or mutant (p53-V143A; Mut) p53 were synchronized in early S phase, challenged with 30 mM HU for 1 h, and immunostained for BRCA1 
and NBS1. Cells were scored for nuclei containing greater than five BRCA1 or NBS1 foci. (c) Effect of mutant p53 in NHFs. NHFs (82-6) were 
synchronized in early S phase, treated with 30 mM HU for 1 h, and immunostained for NBS1 and BRCA1. Nuclei were counterstained with 
DAPI (blue). Bars, 10  m. (d) Quantitation. BSFs with wild-type (WT) or mutant (p53-V143A; Mut) p53 were synchronized, challenged with 
HU, and immunostained as described in part b. Cells were scored for nuclei containing greater than five BRCA1 or NBS1 foci.T
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suggest that BLM may be an important initial coordinator
of processes that ensure the faithful repair of damage during
DNA replication (Fig. 9). In the absence of BLM function,
the majority of cells damaged during S phase die by apopto-
sis. We hypothesize that the survivors may repair the damage
by suboptimal, low fidelity processes and thus may harbor a
high incidence of the chromosomal abnormalities character-
istic of BS cells.
Regarding the cells we generated for this study, we consis-
tently observed a gradual increase in growth rate and loss of
sensitivity to genotoxic stress when BSF and NHF   HM
cells were continually subcultured (unpublished data). For
this reason, we prepared fresh cultures from frozen stocks ev-
ery few weeks. These findings suggest that the genomic insta-
bility caused by BLM deficiency can produce mutational
variants that eventually overtake the culture. Transformed
cells, particularly those in which the p53 pathway is defec-
tive, may be unsuitable for studying normal cellular conse-
quences of BLM deficiency. Lesions in the p53 pathway and/
or the use of asynchronous cultures may also explain appar-
ent discrepancies in the literature, such as the insensitivity of
BLM-null chicken cells to HU (Imamura et al., 2001) or the
resistance of BS lymphoblastoid cells to some DNA damag-
ing agents (Wang et al., 2001).
BS cells are prone to apoptosis
Stalled forks can develop double strand breaks, which typi-
cally cause senescence in NHFs (Robles and Adami, 1998).
However, we observed no evidence of senescence when BSFs
experienced damage during replication; rather, the cells died
by apoptosis. Thus, BLM deficiency renders cells highly sus-
ceptible to apoptosis, suggesting a possible explanation for
the pre- and postnatal growth retardation seen in BS. Endog-
enous oxidative metabolism continually generates DNA le-
sions (Ames, 1998), which can stall replication forks and gen-
erate double strand breaks. Under these conditions, BLM
and other proteins must act quickly to repair the damage. In
the absence of BLM, many cells may fail to repair the damage
rapidly enough, whereupon p53 signals those cells to die. In-
dividuals with BS may continually lose cells, owing to exces-
sive apoptosis, particularly during pre- and postnatal develop-
ment, when cell proliferation is extensive. Excessive apoptosis
would leave many tissues with chronic cellular insufficiency,
and hence small size, thereby explaining the pre- and postna-
tal growth retardation. BS is rare among humans, and it is
hypothesized that many BS embryos die in utero (German,
1997). Consistent with this idea, most blm
 /  mice die be-
fore birth due to massive apoptosis (Chester et al., 1998).
Role of BLM in BRCA1 and NBS1 focus formation
BLM expands the list of proteins that associate with  H2AX
at DNA breaks (Tauchi et al., 2002; Shang et al., 2003; Xu
and Stern, 2003). BLM localized to  H2AX foci within
minutes of their formation. As  H2AX interacts directly
with NBS1 (Kobayashi et al., 2002), BLM may facilitate the
NBS1– H2AX interaction. Consistent with this view, the
HM mutant was proficient at recruiting BRCA1 and NBS1,
despite its inability to prevent apoptosis after DNA damage
during S phase. Thus, although BLM helicase activity is es-
sential for preventing cell death, it is dispensable for rapid
BRCA1/NBS1 recruitment. These findings suggest that
BLM has both an enzymatic role and a structural role in the
rapid response to damage during S phase. Interestingly,
WRN may also have both catalytic and structural roles in
DNA repair (Chen et al., 2003).
BSFs that survive damage during S phase eventually
formed BRCA1 and NBS1 foci, albeit with delayed kinetics.
Thus, BLM is not unconditionally necessary for BRCA1
and NBS1 focus formation, but rather is necessary only for
the rapid response. In the absence of BLM, another RECQ
helicase may substitute for BLM, but its recruitment may be
less efficient or require events that take several hours to com-
plete. BLM also enhanced the ability of BRCA1 and NBS1
to form foci during S phase in undamaged cells. However, of
the BRCA1 and NBS1 foci that formed during S phase,
only 20–30% colocalized with BLM in PML bodies. Why
then are BRCA1 and NBS1 foci so rare in BS cells? One
possibility is that BRCA1 and NBS1 transiently shuttle into
the PML body, where BLM facilitates modifications that al-
low these proteins to form foci outside the PML body. Con-
sistent with this possibility, BLM may be necessary for
NBS1 phosphorylation (Franchitto and Pichierri, 2002).
Yeast RECQ homologues have been proposed to act as
sensors of damage encountered during DNA synthesis (Frei
and Gasser, 2000a,b), a role also ascribed to mammalian
BRCA1 and the MRE11/RAD50/NBS1 complex. Loss of
any of these proteins sensitizes cells to DNA damage and
gives rise to a mutator phenotype. BLM and MRE11/
RAD50/NBS1 were recently identified as part of a large
complex, which BRCA1 was proposed to anchor to the nu-
Figure 9. Model for how BLM and p53 status regulate apoptosis and repair proficiency. Shown are experimentally verified and predicted 
outcomes in normal (wild-type) or BS cells (BLM
  / ), with wild-type or deficient p53 function (p53
 /  or p53
 / ).T
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clear matrix (Wang et al., 2000). Our previous finding that
BLM associates tightly with the nuclear matrix (Bischof et
al., 2001b), and our finding that BLM is required for rapid
recruitment of BRCA1 to damage-induced foci, raises the
possibility that BLM provides the scaffold for assembly of
the BRCA1 repair complex. Assembly of this complex may
prevent the death of cells with damaged replication forks.
This possibility is consistent with the finding that BLM is
rapidly cleaved during apoptosis induced by severe geno-
toxic stress (Bischof et al., 2001a).
Role of p53 in BS phenotypes
p53 was crucial for the apoptotic death of BS cells. This
apoptosis was not accompanied by an increase in BAX or
p21 expression (not depicted), genes for which p53 is a
known transactivator. Thus, p53 may induce apoptosis in-
dependent of its transactivation activity, consistent with
the finding that p53 is transcriptionally inactive during S
phase (Gottifredi et al., 2001; Takimoto and El-Deiry,
2001). p53 may mediate the death of damaged BSFs by di-
rectly inducing mitochondria-mediated apoptosis (Mihara
et al., 2003), or by virtue of it transrepression activity
(Ryan et al., 2001).
Loss of p53 function allowed BS cells to survive replica-
tion stress, but the survivors may acquire chromosomal
aberrations (unpublished data). This scenario provides a
plausible explanation for the extraordinarily high cancer
incidence seen in BS. The excessive apoptosis that likely oc-
curs in the proliferative tissues of BS individuals would also
create a chronic need for cell replacement and hence cell di-
vision, which increases the risk of oncogenic mutations. Be-
cause mutations in the p53 pathway prevent the death of BS
cells, there is intense selection for BS cells that lose p53
function. Loss of p53 function alone is a strong risk factor
for genomic instability and the development of cancer
(Donehower, 1996). However, BLM deficiency may exacer-
bate the loss of genomic integrity due to faulty repair by
BLM-deficient BRCA1/NBS1 complexes. In BS cells with
wild-type p53 function, these complexes assemble after a de-
lay, perhaps owing to time required to recruit a substitute
helicase. In cells with defective p53 function, however, these
complexes assemble rapidly, but may lack the substitute he-
licase and repair may be faulty. This model (Fig. 9) is consis-
tent with recent findings showing that BLM and p53 defi-
ciencies synergize to up-regulate homologous recombination
(Sengupta et al., 2003).
Materials and methods
Cells
NHFs WI-38, HCA2, and 82-6 have been described (Kim et al., 1999; Ita-
hana et al., 2002). BS fibroblasts HG2654 and HG1013 (provided by J.
German, Weill Medical College of Cornell University, New York, NY)
were cultured as previously described (Bischof et al. 2001b). HG2654
(blm
ash) is homozygous for a 6-bp deletion and 7-bp insertion. HG1013
has A inserted at nt 1610 and C→T at nt 2328. NBS1-deficient fibroblasts
GM07166A (from the Coriell Institute for Medical Research, Camden, NJ)
were immortalized with hTERT as previously described (Kim et al., 1999).
BRCA1-mutated cells HCC1937 (from the American Type Culture Collec-
tion) were cultured as previously described (Scully et al., 1999). Jurkat
cells (provided by T. Kohwi-Shigematsu, Lawrence Berkeley National Lab-
oratory) were cultured in RPMI plus 10% fetal calf serum.
Retroviruses
We produced amphotropic retroviruses and infected cells as previously
described (Kim et al., 1999; Itahana et al., 2002). We cloned the wild-
type BLM cDNA into pMSCVhyg (CLONTECH Laboratories, Inc.) and
HM mutant cDNA (Neff et al., 1999) into pBabe-puro (Morgenstern and
Land, 1990).
BLM complemented BSFs and HM-expressing NHFs
hTERT-expressing cells were infected on three consecutive days with con-
trol (insertless), BLM-expressing, or BLM-HM–expressing viruses. To select
for low expressers, we cultured cells in antibiotics (0.75  g/ml puromycin
or 100  g/ml hygromycin) for 1–2 d, allowed recovery for 14–21 d, and
then selected again for 7 d.
Synchronization
For G1 synchronization, we seeded cells in serum-containing medium and,
24 h later, shifted them to medium containing 0.2% serum for 72–96 h. We
then added medium containing 10% serum for 4–6 h. To synchronize cells
at the G1/S boundary and accommodate the different doubling times of
NHFs and BSFs, we serum deprived (0.2%) the cells for 72–96 h, cultured
for 8 (NHF and BSF   BLM) or 12 h (BSF and NHF   HM) in 10% serum,
and then cultured in medium containing 10% serum and either 2  g/ml
aphidicolin or 2 mM HU for 12 (NHF and BSF   BLM) or 16 h (BSF and
NHF   HM). To release from the G1/S block, cells were washed extensively
and cultured in drug-free, serum-containing medium for 1 (NHF and BSF  
BLM) or 3 h (BSF and NHF   HM) before addition of genotoxic agents. To
synchronize cells with mimosine, we cultured cells in low serum (0.2%) for
72 h, added 10% serum for 6 h, and then added 0.25 mM mimosine for
16 h. The cells were washed extensively and then cultured in drug-free se-
rum containing medium for 3 h before addition of genotoxic agents.
Antibodies
We used affinity-purified rabbit (Neff et al., 1999) or goat anti-BLM (C-18
and K-20; Santa Cruz Biotechnology, Inc.), rabbit (Neomarkers) or mouse
(ab-1; Oncogene Research Products) anti-BRCA1, rabbit anti-NBS1 (Novus
Biologicals; Oncogene Research Products), mouse (PG-M3; Santa Cruz
Biotechnology, Inc.) or rabbit (Chemicon) anti-PML, mouse anti-actin
(Chemicon), mouse anti-p53, and mouse anti-tubulin (ab-1; Oncogene Re-
search Products) antibodies. Rabbit anti- H2AX was previously described
(Burma et al., 2001). We detected BrdU incorporation by immunofluores-
cence, using a commercially available kit (Roche).
Immunofluorescence
We seeded 2   10
4 cells in four-well chamber slides, fixed with ice-cold
methanol for 20 min at  20 C or 4% paraformaldehyde for 5 min at room
temperature, permeabilized with 0.5% Triton X-100 for 5 min, and
blocked with 10% serum from the secondary antibody species. We incu-
bated cells in primary antibodies for 1 h at room temperature or overnight
at 4 C and in fluorochrome-conjugated secondary antibodies for 0.5–1 h.
To visualize DNA, the last wash contained 0.4  g/ml DAPI. We mounted
slides in Vectashield and viewed by epifluorescence. Images were cap-
tured with a CCD camera and merged using Adobe Photoshop
®.
Drug treatments and apoptosis assay
We treated cells with etoposide, bleomycin, or HU (Sigma-Aldrich) for 1 h
at the indicated concentrations, washed, and cultured in drug-free me-
dium for 6 h. We detected apoptosis by collapse of mitochondrial mem-
brane potential using the MitoCapture reagent (Biovision) (Kaminker et al.,
2001), morphology of nuclei after DAPI staining, and caspase-3 activity
using a commercially available kit (Oncogene Research Products). In
brief, cell lysates were incubated with a synthetic caspase-3 substrate con-
jugated to a colorimetric tag in the presence or absence of the caspase-3
inhibitor DEVD-CHO for 5 h. Caspase-3 activity is proportional to optical
density at 405 nm. The graph shows activity in arbitrary units.
Western analysis
We prepared protein lysates in 5% SDS, separated 30  g protein using
4–15% SDS-PAGE, transferred the proteins to a nylon membrane, blocked,
and incubated with primary and secondary antibodies, as previously de-
scribed (Bischof et al., 2001b). We detected secondary antibodies by ECL
(Amersham Biosciences).
Immunoprecipitation
We employed a protocol previously described (Yannone et al., 2001). We
precleared 500–1,000  g cell lysate with ultra-link beads (Pierce ChemicalT
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
1208 The Journal of Cell Biology | Volume 162, Number 7, 2003
Co.), incubated the supernatant with either goat anti-IgG or anti-BLM anti-
bodies overnight at 4 C, and clarified the supernatants by centrifugation.
We incubated the supernatants with fresh ultra-link beads, washed the
beads, and released the bound proteins using Laemmli sample buffer. We
separated the released proteins by 4–15% SDS-PAGE, as previously de-
scribed (Bischof et al., 2001b).
Online supplemental material
The supplemental material (Figs. S1–S5) is available at http://www.jcb.org/
cgi/content/full/jcb.200304016/DC1. The supplemental figures show that
low dose HU causes apoptosis in BSFs (Fig. S1), unmodified BSFs behave
similarly to hTERT-immortalized BSFs (Fig. S2), BLM localizes to g-H2AX
foci in BLM-complemented cells (Fig. S3), BLM localizes to g-H2AX foci
after replication stress in BRCA1 mutant or NBS1-deficient cells (Fig. S4),
and BRCA1 and NBS1 foci form in BS cells after low dose HU or mimosine
synchronization (Fig. S5).
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